Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 03/01/24
Wall Street Analysts Think Zentalis Pharmaceuticals, Inc. (ZNTL) Could Surge 136.44%: Read This Before Placing a BetZacks Investment Research • 02/28/24
Zentalis Pharmaceuticals Reports Full Year 2023 Financial Results and Operational UpdatesGlobeNewsWire • 02/27/24
Down -19.06% in 4 Weeks, Here's Why You Should You Buy the Dip in Zentalis Pharmaceuticals, Inc. (ZNTL)Zacks Investment Research • 02/14/24
Zentalis Pharmaceuticals to Participate in the Oppenheimer Healthcare Life Sciences ConferenceGlobeNewsWire • 02/13/24
IMPORTANT INVESTOR ALERT: The Schall Law Firm Encourages Investors in Zentalis Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmAccesswire • 01/09/24
Immunome Exclusively Licenses Zentalis ROR1 Antibody-Drug Conjugate and Proprietary Technology PlatformBusiness Wire • 01/08/24
INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Zentalis Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmAccesswire • 01/08/24
INVESTOR ACTION NOTICE: The Schall Law Firm Encourages Investors in Zentalis Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmAccesswire • 12/28/23
SHAREHOLDER ACTION NOTICE: The Schall Law Firm Encourages Investors in Zentalis Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmAccesswire • 12/13/23
SHAREHOLDER ACTION ALERT: The Schall Law Firm Encourages Investors in Zentalis Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmAccesswire • 12/04/23
INVESTOR ACTION ALERT: The Schall Law Firm Encourages Investors in Zentalis Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmAccesswire • 11/22/23
ONGOING INVESTIGATION ALERT: The Schall Law Firm Encourages Investors in Zentalis Pharmaceuticals, Inc. with Losses of $100,000 to Contact the FirmAccesswire • 11/21/23
Zentalis: Latest Market Sell-Off Looks Justified With Data Catalysts Long Way OffSeeking Alpha • 11/14/23
Zentalis Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational UpdatesGlobeNewsWire • 11/06/23
Zentalis Pharmaceuticals Reports Second Quarter 2023 Financial Results and Operational UpdatesGlobeNewsWire • 08/09/23
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 08/01/23
Matrix Capital Infuses $108 Million Into Zentalis Toward Promising Cancer Therapeutics24/7 Wall Street • 06/23/23
Zentalis Pharmaceuticals Announces Pricing of Underwritten Offering of Common StockGlobeNewsWire • 06/15/23
Zentalis Announces Intermittent Azenosertib Monotherapy Dosing Nearly Doubles Efficacy Over Continuous DosingGlobeNewsWire • 06/06/23